Reviewing Nautilus Biotechnology (NASDAQ:NAUT) and Revvity (NYSE:RVTY)

Nautilus Biotechnology (NASDAQ:NAUT) and Revvity (NYSE:RVTY) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Profitability

This table compares Nautilus Biotechnology and Revvity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-28.85%	-24.93%
Revvity	9.81%	7.68%	4.62%

Valuation & Earnings

This table compares Nautilus Biotechnology and Revvity”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$63.67 million	($0.56)	-1.64
Revvity	$2.76 billion	4.67	$270.39 million	$2.21	48.44

Revvity has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Nautilus Biotechnology has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Revvity has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Insider & Institutional Ownership

50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 86.7% of Revvity shares are held by institutional investors. 40.5% of Nautilus Biotechnology shares are held by insiders. Comparatively, 0.6% of Revvity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for Nautilus Biotechnology and Revvity, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1	1	1	0	2.00
Revvity	0	4	8	1	2.77

Nautilus Biotechnology presently has a consensus price target of $2.42, suggesting a potential upside of 162.57%. Revvity has a consensus price target of $136.25, suggesting a potential upside of 27.27%. Given Nautilus Biotechnology’s higher possible upside, research analysts plainly believe Nautilus Biotechnology is more favorable than Revvity.

Summary

Revvity beats Nautilus Biotechnology on 11 of the 14 factors compared between the two stocks.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

About Revvity

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.